Aptose Biosciences Inc(APTO) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1b clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase 1a/b clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.

Current Price

$4.92

RSI

57.307

Beta:

1.295049

November 10, 2020
1.2M
-8.3M

-93.586 %
-40.199 %

$0
$124,156
$168,807
$43,023
$100,023
$24,001
-Infinity %
-35.963 %
292.363 %
-132.487 %
316.751 %

$-26,277,000
$0
$0
$0
$0
$0
0.000 %
0.000 %
0.000 %
0.000 %
0.000 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.